evidence based decision making for the rational drug list (rdl)
Post on 14-Dec-2014
1.301 Views
Preview:
DESCRIPTION
TRANSCRIPT
EVIDENCE BASED DECISION MAKING FOR THE RATIONAL DRUG LIST (RDL)
DR MAISA AL SAKET
DG JOINT PROCUREMENT DEPARTMENT
Committee 2 Evidence Based
MeTA 10/04/23 1
10/04/23MeTA 2
Members of Committee 2
Dr Maisa Al Saket/ G.D. - JPD Dr Riham Al Natheef/ Supply Director- RMS Dr Musallam Qatarneh/ Purchasing & Supply
Director/ MOH Dr Ibrahim Abbadi/ Jordan University Dr Lama Al Homoud/ Clinical Pharmacy Director -
MOH Dr Hanan Sboul/ SG. - JAPM
Background
There will be a transparent evidence- based process in place for listing drugs
Conducting Pharmaco-economic studies is crucial for the development of an effective and affordable national drug list
It is crucial that the public health institutions are supportive of the process and believe in the integrity of the final RDL in order to promote the adherence to it by prescribers and institutions
10/04/23MeTA 3
MeTA Work plan- Jordan
Encouraging best practice/ improve rational use of medicines
Evidence based decision making for the rational drug list RDL
Capacity building in Civil society
10/04/23MeTA 4
Evidence- based decision making can be achieved through:
Assessment of Current Committees’ constitution, TOR and Procedures
Assessment of current classification of drugs Raising awareness among stakeholders and
building capacity Monitoring & evaluation
10/04/23MeTA 5
10/04/23MeTA 6
Assessment of Current Committees’ constitution, TOR and Proceduressub-activities: Review constitutions, TOR and SOPs of various
committees involved in the selection of drugs in the RDL (requires COI declaration, and COI guidelines) and benchmark against best practices
Recommend regulations for the amendments- if needed Review criteria for adding and deleting drugs to and
from the RDL Recommend evidence based regulations for the
addition / deletion criteria Adopt the recommendations
10/04/23MeTA 7
Assessment of current classification of drugs
• Formulate a technical working group to review the classification of drugs (restricted, unrestricted & authority required) in the RDL
• Recommend detailed evidence based regulations for the implementation of the classification of drugs
• Adopt the classification & the detailed regulations for the implementation of the classification
Technical working group represents
JFDA/ RDU JPD Ministry of Health/ Clinical Pharmacy , Supply Departments Royal Medical Services/ Drug &Pharmacy, Supply
Departments Academia/ PhD in clinical pharmacy Internal medicine consultant Pharmaco-economist
10/04/23MeTA 8
Raising awareness among stakeholders and building capacity
Organize workshops to raise awareness and reach a common understanding on the concepts of role of pharmacy & therapeutic committee (PTC), evidence-based medicine (EBM), pharmaco-economics, transparency & accountability
Train policy makers and technical committees in NICE/UK
Organize workshop on use of cost effectiveness tools
10/04/23MeTA 9
10/04/23MeTA 10
Monitoring and Evaluation
Monitor and Evaluate the adoption and implementation of recommendations in previous activities, according to set KPI’s
Evidence- based decision making activities KPI’s include:
Constitution, TOR & SOPs for committees are in place
Guidelines for addition/ deletion & classification are in place
Workshops conducted Reports to be delivered
10/04/23MeTA 11
Thank you
10/04/23MeTA 12
top related